SCHEDULE: Squadron Funds Report 1.6% Stake in NextCure

Squadron Master Fund LP, along with affiliated entities and individuals, has reported beneficial ownership of approximately 1.6% of NextCure, Inc.'s common stock.

Summary

• Squadron Master Fund LP, Squadron Capital Management LLC, Matthew Sesterhenn, and William Blank have collectively reported beneficial ownership of 64,464 shares of NextCure, Inc. common stock.
• This ownership stake represents approximately 1.6% of the total outstanding common stock.
• The filing is an amendment to a Schedule 13G, indicating a change in ownership reporting.
• Squadron Capital Management LLC acts as the investment adviser to Squadron Master Fund LP.
• Matthew Sesterhenn and William Blank, as Partners of Squadron Capital Management LLC, may be deemed beneficial owners due to their control over investment and voting discretion.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting ownership stakes and not containing operational or financial performance updates.

Positives

• The filing clearly discloses the beneficial ownership stake, providing transparency to the market.
• The reporting entities are registered investment advisers, suggesting a professional approach to investment.

Negatives

• The filing does not provide any information on the performance or strategy of NextCure, Inc., limiting insight into the investment's rationale.
• The disclaimer of beneficial ownership by Squadron Capital Management LLC, Mr. Sesterhenn, and Mr. Blank, while legally permissible, can create ambiguity regarding ultimate control.

Risks

• The filing does not contain specific forward-looking statements or risk factors related to NextCure, Inc.'s business operations.
• The disclaimer of beneficial ownership could imply a lack of direct control or influence over the company's strategic direction by the reporting persons.

Future Outlook

No forward-looking statements or specific future outlook for NextCure, Inc. are provided in this filing.

Management Comments

• Squadron Capital Management, LLC, which serves as investment adviser to private funds, including but not limited to Squadron Master Fund LP (collectively, the "Funds"), may be deemed to be the beneficial owner of all shares of Common Stock held by the Funds.
• Mr. Sesterhenn and Mr. Blank, as Partners of Squadron Capital Management, LLC, with the power to exercise investment and voting discretion, may be deemed to be the beneficial owner of all shares of Common Stock held by the Funds.
• Pursuant to Rule 13d-4 under the Securities Exchange Act of 1934, as amended, Squadron Capital Management, LLC and Mr. Sesterhenn and Mr. Blank expressly disclaim beneficial ownership over any of the securities reported in this statement, and the filing of this statement shall not be construed as an admission that Squadron Capital Management, LLC or Mr. Sesterhenn and Mr. Blank are the beneficial owner of any of the securities reported herein.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes. This filing indicates Squadron's interest in NextCure, Inc., a biotechnology company, but provides no operational context for this interest.

Stakeholder Impact

• Shareholders: Increased transparency regarding significant beneficial ownership, potentially indicating institutional interest.
• Management of NextCure, Inc.: Awareness of a notable institutional stakeholder.

Next Steps

• Continued monitoring of NextCure, Inc.'s filings for any further changes in beneficial ownership or operational updates from Squadron Master Fund LP and its affiliates.

Key Dates

Keywords

NextCure, Squadron Master Fund, Squadron Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, SEC Filing